если переводить все до конца:
мутация доступных растворителю аминокислотных остатков [АТФ-связывающего кармана киназного домена]
или мутация в доступном растворителю участке


Somatic point mutations in the kinase domain of NTRK that confer resistance to the type I inhibitors, larotrectinib and entrectinib, have been identified in pre-clinical screens and clinical samples14,15,17,20. These mutations commonly reside in the catalytic region of the kinase domain, and include residues in the solvent front of the ATP-binding pocket (solvent-front mutations), the gatekeeper residue that is a conserved hydrophobic amino acid in the active site (gatekeeper mutation), or the amino acid preceding the activation loop DFG motif (xDFG mutation).
https://www.nature.com/articles/s42003-020-01508-w

тут можно посмотреть схемку https://www.tptherapeutics.com/corporate/our-science/